The manageable safety profile and promising anti-tumor activity of the combination of onvansertib/FOLIFRI/bevacizumab in the second-line treatment of patients with KRAS-mutant metastatic colorectal cancer (mCRC) was reported. Here, KRAS is linked to metastatic colorectal cancer.